RECORD // Company

Syndax Pharmaceuticals Inc

Built 2026-11-21T11:30:07Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (6)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Syndax Pharmaceuticals, Inc. · Breach states · same registered legal name as 'Syndax Pharmaceuticals Inc' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Syndax Pharmaceuticals · Ctgov · exact name match to 'Syndax Pharmaceuticals Inc' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SYNDAX PHARMACEUTICALS INC · East licences · same registered legal name as 'Syndax Pharmaceuticals Inc' Possible match based on name, not a shared identifier. Compare the records. Compare
  • SYNDAX PHARMACEUTICALS, INC. · East licences · same registered legal name as 'Syndax Pharmaceuticals Inc' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Syndax Pharmaceuticals, Inc. · East licences · same registered legal name as 'Syndax Pharmaceuticals Inc' Possible match based on name, not a shared identifier. Compare the records. Compare
  • SYNDAX PHARMACEUTICALS, INC. · Ny corps · same registered legal name as 'Syndax Pharmaceuticals Inc' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-02 · accession 0001193125-26-443625

ItemValuePeriodFormFiledAccessionReport
Revenue$83,298,0003 months ended 2026-09-3010-Q2026-11-020001193125-26-4436252026-11-21 11:30 UTCReport an error
Net income (loss)$-49,433,0003 months ended 2026-09-3010-Q2026-11-020001193125-26-4436252026-11-21 11:30 UTCReport an error
Interest expense$2,0003 months ended 2026-09-3010-Q2026-11-020001193125-26-4436252026-11-21 11:30 UTCReport an error
Cash and cash equivalents$135,941,000at 2026-09-3010-Q2026-11-020001193125-26-4436252026-11-21 11:30 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001395937
Ticker
SNDX
EIN
320162505
CUSIP
87164F105
Record ID
sx:sec:0001395937

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

40 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-12SEC EDGAR company profile2026-11-21 11:30 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-12SEC EDGAR company profile2026-11-21 11:30 UTCReport an error
State of incorporationDE2026-11-12SEC EDGAR company profile2026-11-21 11:30 UTCReport an error
Fiscal year end (MMDD)12312026-11-12SEC EDGAR company profile2026-11-21 11:30 UTCReport an error
Business address730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 100172026-11-12SEC EDGAR company profile2026-11-21 11:30 UTCReport an error
ExchangesNasdaq2026-11-12SEC EDGAR company profile2026-11-21 11:30 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$172,352,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:30 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-285,422,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:30 UTCReport an error
Total assets (at 2025-12-31)$529,706,0002025-12-3110-K, XBRL Assets2026-11-21 11:30 UTCReport an error
Stockholders' equity (at 2025-12-31)$64,630,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:30 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$134,930,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:30 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-322,980,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:30 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$187,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:30 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,521,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:30 UTCReport an error
Form D total offering amount (D filed 2015-08-28)$61,252,4622015-08-28D2026-11-21 11:30 UTCReport an error
Form D total amount sold (D filed 2015-08-28)$61,252,4622015-08-28D2026-11-21 11:30 UTCReport an error
Form D industry groupPharmaceuticals2015-08-28D2026-11-21 11:30 UTCReport an error
Form D revenue rangeDecline to Disclose2015-08-28D2026-11-21 11:30 UTCReport an error
Form D date of first sale2015-08-212015-08-28D2026-11-21 11:30 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-02)On November 2, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation announcing its financial results for the quarter ended September 30, 2026. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The information contained in this Item 2.02 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference…2026-11-02SEC EDGAR 8-K 0001193125-26-443613 (text as filed, excerpt)2026-11-21 11:30 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-04)On August 4, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation announcing its financial results for the quarter and year ended June 30, 2026. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The information contained in this Item 2.02 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by…2026-08-04SEC EDGAR 8-K 0001193125-26-332736 (text as filed, excerpt)2026-11-21 11:30 UTCReport an error
Employer name (as filed)Syndax Pharmaceuticals, Inc2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:30 UTCReport an error
Certified LCAs12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:30 UTCReport an error
Certified LCAs later withdrawn02026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:30 UTCReport an error
Total worker positions on certified LCAs12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:30 UTCReport an error
Top job titles (title, LCA count)Director, IT R&D Technology Platforms and Operations (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:30 UTCReport an error
Wage offered, annualized (n, min, median, max)median $220,000 (range $220,000-$220,000, 1 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:30 UTCReport an error
Worksite statesNC2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:30 UTCReport an error
Plan (pension, plan no. 001)SYNDAX PHARMACEUTICALS, INC. 401(K) PLAN: 354 participants, assets $38,504,4212025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:30 UTCReport an error
Plan (welfare, plan no. 501)SYNDAX PHARMACEUTICALS HEALTH & WELFARE BENEFITS PLAN: 536 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:30 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$197,177,3532026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #2 (13F as filed): Kynam Capital Management, LP$175,993,9642026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #3 (13F as filed): GOLDMAN SACHS GROUP INC$128,127,2532026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #4 (13F as filed): STATE STREET CORP$123,693,1492026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #5 (13F as filed): BANK OF AMERICA CORP /DE/$88,425,7552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$85,863,7192026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #7 (13F as filed): DEERFIELD MANAGEMENT COMPANY, L.P.$82,628,6142026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #8 (13F as filed): Eversept Partners, LP$61,168,8712026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$56,499,5632026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error
Largest institutional holder #10 (13F as filed): Hood River Capital Management LLC$56,055,1392026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:30 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.